Our Services and Platform Technologies

We offer access to world class platform technologies and a complete range of services from early in silico discovery through to preclinical studies.

Our Services

Our highly talented teams of scientists can deliver specific services as well as running complete drug discovery projects, with teams from different departments working closely together to provide a fully integrated approach.

rxbiologics

IN SILICO DESIGN

Cutting-edge in silico discovery and development of small molecule therapeutics, antibodies and biopharmaceuticals, plus enzyme engineering. Home of RxNfinity, the chemical space exploration platform.
rxbiologics

ANTIBODY DISCOVERY

Isolation of fully human antibodies using our ‘Galaxy’ platform. Immune library generation & humanisation expertise.

Chemistry

Generation of high quality hit material, development candidates, and active pharmaceutical ingredients as quickly and cost-effectively as possible.

IN VITRO

In vitro assay design and development including cell-based and plate-based assays, molecular and biochemical assays and ICC.

DROSOPHILA

Design and development of assays using Drosophila melanogaster, enabling drug screening in a whole organism with a quick turnaround.

Preclinical

Complete in vivo and histology services covering a wide range of disease areas and therapeutic approaches.

Proteomics

Using ProQuant®, our proteomics platform for performing LC-MS/MS bottom-up proteomics on a wide range of biological samples.

Project Management

Client-focused project management, driven by best practices, with experienced project managers that can input at all stages from concept to clinic.

Our Platform Technologies

Our proprietary technologies give a unique advantage to your drug discovery project.

rxbiologics

Antibody Discovery Platform

Proprietary human antibody discovery platform, which combines the biology of B-cell selection and in vitro methodologies to maximise diversity and find high quality leads.

Dynamic Chemical Space

First commercially available dynamic chemical space allowing in silico screening of billions of novel small molecules against a target in a matter of weeks.

Proteomics Platform

Unique proteomics platform offering quantitative precision and unbiased analysis of proteins and their modifications in simple and complex matrices.

RxCelerate offers a unique business model catering to both small molecules and biologics. We work with you to drive your asset through drug discovery, preclinical research and beyond.

Our combination of integrated teams and unique technologies allows RxCelerate to develop the optimal drug discovery strategy to deliver pharma-grade drug candidates quickly and at a fraction of the cost of traditional approaches.